kinase

Resistance mechanisms to FLT3 inhibitors in AML 3:14
Resistance mechanisms to FLT3 inhibitors in AML
Katherine Smith • 5 Oct 2017
Two important therapies for ALL 2:51
Two important therapies for ALL
Dieter Hoelzer • 22 Jun 2017
2:35
CLL update from ICML17: Current treatment and future directions for patients
Barbara Eichhorst
The potential clinical implications of targeted therapies for DLBCL and why the situation is complex 1:47
The potential clinical implications of targeted therapies for DLBCL and why the situation is complex
Clemens Schmitt • 23 Sep 2016
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals